Välkommen till Via TT - det enkla pressverktyget

Under dagen har regeringen tillsatt en utredning om hur förbud mot pälsdjursuppfödning ska införas i Sverige. Detta efter ett löfte som gavs hösten 2023 och på grund av ”djuretiska diskussioner” som har letts av Djurens Rätt i över 50 år. Djurens Rätt firar denna framgång och uppmanar till att utredningen sker skyndsamt.

From bell foundry to global player In its anniversary year, HEIDELBERG heads into the future with a clear growth strategy Speedmaster series perpetuates success story started by legendary “Original Heidelberger Tiegel” – the 1921 springboard to a world-leading position Milestones in the history of HEIDELBERG

Aachen, Germany & Toronto, Canada, 24 February 2025 – Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, non-opioid pain patch indicated for the management of neuropathic pain.

Munich Declaration 2025 On the occasion of the 61st Munich Security Conference (MSC), leading European policymakers, business leaders and security experts have presented the Munich Declaration 2025 — a bold vision for strengthening Europe's defence and economic competitiveness. The declaration is issued by the Europe Panel and its committee. It was initiated by José Manuel Durão Barroso (Former President of the European Commission), Klaus Regling (Former Managing Director of the ESM), André Loesekrug-Pietri (Chairman and Scientific Director of JEDI), Othmar Karas (President European Forum Alpbach), Antonella Mei-Pochtler (Vice President European Forum Alpbach), Andreas Treichl (Chairman Erste Foundation Austria) and Martin Schoeller (Entrepreneur). The declaration outlines concrete steps to enhance Europe's security architecture, technological leadership, and strategic autonomy in an increasingly volatile and protectionist global environment. Key Commitments of the Munich Declaration 2

Revenue grew 3 percent on a comparable basis to €18.4 billion (Q1 2024: €17.7 billion) Orders in Q1 2025 declined 8 percent on a comparable basis to €20.1 billion (Q1 2024: €21.6 billion) Profit Industrial Business totaled €2.5 billion (Q1 2024: €2.7 billion); profit margin Industrial Business was 14.1 percent (Q1 2024: 15.8 percent) Free cash flow at Group level rose sharply to €1.6 billion (Q1 2024: €1.0 billion) Net income soared 52 percent to €3.9 billion (Q1 2024: €2.5 billion), benefiting from a €2.1 billion gain (after tax) from the sale of Innomotics Outlook for fiscal 2025 confirmed Virtual Annual Shareholders’ Meeting to vote on dividend proposal of €5.20 per share for fiscal 2024 (fiscal 2023: €4.70)

Q3 sales at previous year’s level and adjusted EBITDA margin improves significantly to 9.2 percent Incoming orders up 8.3 percent for Q3 and 7.7 percent after nine months compared with previous year High order backlog points to strong final quarter Full-year forecast confirmed, adjusted EBITDA margin to rise to up to around 8 percent in FY 2025/2026 Packaging remains a growth driver Growth strategy promises sales potential of over € 300 million in medium term

The National Press Club in Washington has issued a statement demanding the immediate release of journalist Mr. Dawit Isaak, a prisoner of conscience and the world’s longest arbitrarily detained journalist. Mr. Dawit Isaak, the 2024 Edelstam Prize Laureate, has been unlawfully imprisoned since 2001 without trial. He has not been charged with a crime, nor has he been allowed to speak with his lawyer.

Los Angeles/DNA – High levels of governance have masked a slow decline in Germany, with political, economic, and social fractures "festering over years", a new scientific report released only weeks ahead of the February 23 parliamentary elections concludes.

Regeringen lovade redan hösten 2023 att minkfarmerna skulle få avvecklingsstöd för att lägga ned sin verksamhet. Nu är det klart att 180 miljoner kronor ska betalas ut till före detta minkfarmer. Samtliga förväntas vara tomma på djur senast i juni. Djurens Rätt är glada att det innebär en fullständig avveckling av en oetisk industri, men påpekar att det samtidigt behövs en utredning om förbud.

Aachen, Germany, 09 January 2025 – Grünenthal announced today that Prof. Dr. Uli Brödl will assume the role of Chief Scientific Officer (CSO) and Member of the Corporate Executive Board, effective 01 February 2025. Uli Brödl has more than 15 years of industry experience. He joins Grünenthal from Boehringer Ingelheim, where he served as Corporate Senior Vice President, Head of Global Clinical Development & Operations, and member of Boehringer Ingelheim's Venture Fund Investment Committee. In his most recent role, he oversaw end-to-end clinical development and operations activities across therapeutic areas and worked at the interface of R&D, Commercial, and Market Access functions. He has a proven track record of bringing innovative medicines to patients, including Empagliflozin, an oral anti-diabetic medicine. Earlier in his career, Uli Brödl led Boehringer Ingelheim's Canadian medical organisation and gained extensive market experience. In parallel, he founded and co-chaired the BI Can

The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures per year in the U.S.[2] QUTENZA® is a topical system, non-systemic, non-opioid pain treatment that is currently approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Topline results are expected in Q4 2025 and Averitas Pharma aims to submit a supplemental new drug application (sNDA) for a US label extension in 2026, subject to positive data.

Aachen, Germany, 22 October 2024 – Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the pharmacokinetic characteristics of the compound after single and multiple ascending doses. The results of the trial are expected in Q3 2025. “Grünenthal pioneered the research into NOP receptor agonists to deliver a unique and transformative first-in-class therapy option to millions of patients suffering from chronic pain,” says Gillian Burgess, Head of Research, Grünenthal. “With a unique mechanism of action for treating chronic pain, these molecules have the potential to deliver robust pain relief combined with an improved safety profile compared to the available standard of care.” Pre-clinical data show that NOP receptor agonists have the potential to act as pot

The sluggish rate of progress made in the energy transition is putting the goal of reducing greenhouse gas emissions to zero by the middle of the century at risk. A comparison of four European countries shows that Denmark and Norway are making significant strides in transitioning to renewable heating and electricity. Norway is also advancing quickly in the road transport sector. The UK and Germany continue to face several challenges.

Leading Swiss data center provider Green is building another high-performance data center on the Metro-Campus Zurich West. The demand for computing power has risen sharply.

Strong second half-year expected thanks to high order backlog As expected, sales and EBITDA down year-on-year in the first quarter due to reluctance to buy ahead of drupa Growth potential: cooperation with Canon for industrial digital printing in the commercial sector Annual forecast confirmed

(Linz, Austria). The European smartphone company emporia is launching the successor to its previous bestseller on the market for the past 2 years. The emporiaSMART.6lite follows on from the emporiaSMART.5 - which has been voted “senior smartphone of the year” in Germany three times in a row. emporia is the unrivalled market leader for easy-to-use smartphones in Germany. According to the latest GfK figures, the Austrian company has a market share of around 66 per cent in this segment. With the new emporiaSMART.6lite, which is not only easy to use but it is packed with the performance of a standard modern smartphone with great cameras, great security and more, to further expand the companies aims. Design and development made in Europe. Whether in a handbag, breast pocket, jacket, belt, waist or shoulder bag or front and back trouser pocket - the compact emporiaSMART.6lite fits in everywhere. And while compact in size, the screen is a comfortable 5.45 inches, that is large enough to ensur

Grünenthal acquires the pharmaceutical company Valinor Pharma, further strengthening Grünenthal’s footprint in the United States. With the acquisition, Grünenthal becomes the global owner of Movantik® / Moventig® (naloxegol). Since 2017, Grünenthal has invested more than €2 billion in successful M&A transactions, significantly strengthening its profitability.

Investment of more than €80 million to modernise Latin American production sites. In Santiago de Chile, a 3,500-square-metre solids plant has been completely refurbished, creating a world-class manufacturing facility with a production capacity of 1.8 billion tablets annually. In Quito, Ecuador, a new 1,800-square-metre plant will enable the production of 300 million high-quality tablets annually for pain patients in 17 European countries.

Inför det kommande valet till Europaparlamentet har Djurens Rätt arbetat för att göra det enklare för de väljare som vill rösta på en djurvänlig kandidat. Nu presenteras sammanställningen över vilka svenska kandidater som säger att de kommer att verka för djuren om de får en plats i Europaparlamentet under den kommande mandatperioden.

As the European elections draw near, we, A Non Smoking Generation, alongside the European Network for Smoking and Tobacco Prevention, are compelled to address a pressing issue regarding the proliferation of new nicotine products across the continent. Therefore, we are launching an information campaign targeting all EU citizens, while simultaneously demanding all candidates to the European Parliament elections to pledge swift and adequate measures to protect the next generation from harmful nicotine addiction.